Sheridan, Wyoming, June 05, 2025 (GLOBE NEWSWIRE) — ByteBrain LLC, an rising AI analysis and consulting agency, has introduced the launch of MEDRAIL, an clever platform designed to assist pharmaceutical corporations run quicker, safer, and extra adaptive medical trials.
ByteBrain
MEDRAIL, quick for MEDical Reinforcement-based Agentic Intelligence for Lifesciences, brings collectively the ability of synthetic intelligence and superior compliance automation to modernize the medical trial course of. The corporate has filed for a U.S. patent below the USPTO’s Monitor One program to fast-track safety of the platform’s novel expertise.
Priyanshu Sharma, co-founder of ByteBrain
“Scientific trials are sometimes gradual, pricey, and troublesome to handle, particularly in fast-evolving medical landscapes,” mentioned Priyanshu Sharma, Co-Founding father of ByteBrain. “MEDRAIL helps organizations react to security information quicker, cut back handbook errors, and keep compliant with international regulatory requirements.”
A Smarter Strategy to Run Scientific Trials
MEDRAIL makes use of a workforce of specialised AI brokers, every skilled to deal with duties like affected person recruitment, protocol monitoring, security surveillance, and documentation compliance. These brokers work collectively in actual time, adjusting to trial information and new regulatory tips as they emerge.
Priyanshi Bhatnagar, co-founder of ByteBrain
“What makes MEDRAIL distinctive is its built-in security verification and explainability,” added Priyanshi Bhatnagar, Co-Founder. “Each protocol change, each suggestion, it’s backed by formal logic, clear reasoning, and a full audit path.”
Key Advantages of MEDRAIL:
- Quicker protocol design and amendments
- Early detection of issues of safety utilizing AI
- Constructed-in compliance with FDA, HIPAA, and ICH-GCP requirements
- Automated documentation with full audit logs
- Seamless integration with present medical workflows
Why It Issues
Scientific trials can price as much as $3 billion per accepted drug and take greater than a decade to finish. ByteBrain believes that smarter, AI-assisted trial methods can reduce that point considerably, probably saving tens of millions and accelerating time-to-market for life-saving therapies.
The platform was developed with enter from medical analysis specialists throughout pharma, educational medical facilities, and regulatory affairs. Preliminary suggestions has been constructive, with ByteBrain getting ready to launch technical papers and pilot research within the coming months.
About ByteBrain
ByteBrain LLC is a research-first AI firm specializing in advanced, regulated industries. Based mostly within the U.S., it combines consulting providers with the event of superior IP in healthcare, finance, and enterprise AI methods. MEDRAIL is the agency’s flagship healthtech innovation and a part of its broader mission to construct human-centered, compliance-ready AI options.
